Lpath, Inc. is a biotechnology company. The Company is focused on the discovery and development of lipidomic-based therapeutic antibodies. The Company has three product candidates, which include iSONEP, ASONEP and Lpathomab. The Company utilizes ImmuneY2 technology for the production of its antibodies. iSONEP is the ocular formulation of sonepcizumab, a humanized monoclonal antibody (mAb) against sphingosine-1-phosphate (S1P), a bioactive lipid implicated in the progression of many diseases. ASONEP is the systemic formulation of sonepcizuma, a mAb against S1P, a validated angiogenic factor and validated mediator of lymphocyte trafficking. Lpathomab is a mAb against lysophosphatidic acid (LPA), a tumorigenic and metastatic agent and a validated contributor to neuropathic pain.
